相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Jitka Fucikova et al.
CLINICAL CANCER RESEARCH (2019)
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Ki Hyung Kim et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma
Ying Dai et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer
Maureen L. Drakes et al.
JOURNAL OF OVARIAN RESEARCH (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
Galaxia M. Rodriguez et al.
CANCERS (2018)
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
S. J. L. Mesnage et al.
ANNALS OF ONCOLOGY (2017)
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Charlotte S. Lo et al.
CLINICAL CANCER RESEARCH (2017)
T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
Jian-Feng Liu et al.
MOLECULAR ONCOLOGY (2017)
Immune Cell Population in Ovarian Tumor Microenvironment
Dong Li Cai et al.
JOURNAL OF CANCER (2017)
Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
Stefanie Aust et al.
SCIENTIFIC REPORTS (2017)
Role of TIM-3 in ovarian cancer
Y. Xu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Silvia Darb-Esfahani et al.
ONCOTARGET (2016)
Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Bohm et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
John R. Webb et al.
GYNECOLOGIC ONCOLOGY (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2015)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Ruea-Yea Huang et al.
ONCOTARGET (2015)
Platinum resistant ovarian cancer: What is it, who to treat and how to measure benefit?
Alison Davis et al.
GYNECOLOGIC ONCOLOGY (2014)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
PD-1 as a potential target in cancer therapy
David F. McDermott et al.
CANCER MEDICINE (2013)
Tim-3, a negative regulator of anti-tumor immunity
Ana Carrizosa Anderson
CURRENT OPINION IN IMMUNOLOGY (2012)
T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer
Danian Tong et al.
MOLECULAR BIOLOGY REPORTS (2012)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Qing Zhou et al.
BLOOD (2011)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Feng Qian et al.
CANCER RESEARCH (2009)
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
Tomoko Inaba et al.
GYNECOLOGIC ONCOLOGY (2009)
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
R. Houston Thompson et al.
CLINICAL CANCER RESEARCH (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)